Imprimis Pharmaceuticals (IMMY) Stock Price Down 5.5%

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)’s share price traded down 5.5% during mid-day trading on Monday . The company traded as low as $4.90 and last traded at $5.00. 518,922 shares changed hands during trading, an increase of 94% from the average session volume of 267,697 shares. The stock had previously closed at $5.29.

The company has a debt-to-equity ratio of 2.84, a quick ratio of 0.88 and a current ratio of 1.13.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last released its quarterly earnings data on Tuesday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.03). Imprimis Pharmaceuticals had a negative net margin of 16.81% and a negative return on equity of 231.16%. The firm had revenue of $10.74 million during the quarter.

In related news, Director Robert J. Kammer sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $3.00, for a total value of $30,000.00. Following the completion of the transaction, the director now directly owns 909,827 shares of the company’s stock, valued at approximately $2,729,481. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 30,000 shares of company stock valued at $102,100 over the last ninety days. 13.78% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMMY. Northern Trust Corp increased its stake in Imprimis Pharmaceuticals by 145.8% in the 1st quarter. Northern Trust Corp now owns 67,013 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 39,750 shares in the last quarter. Birchview Capital LP purchased a new position in Imprimis Pharmaceuticals in the 2nd quarter valued at approximately $396,000. Granite Investment Partners LLC increased its stake in Imprimis Pharmaceuticals by 153.8% in the 2nd quarter. Granite Investment Partners LLC now owns 170,962 shares of the specialty pharmaceutical company’s stock valued at $376,000 after purchasing an additional 103,607 shares in the last quarter. Ardsley Advisory Partners increased its stake in Imprimis Pharmaceuticals by 42.9% in the 2nd quarter. Ardsley Advisory Partners now owns 100,000 shares of the specialty pharmaceutical company’s stock valued at $220,000 after purchasing an additional 30,000 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Imprimis Pharmaceuticals by 104.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 117,990 shares of the specialty pharmaceutical company’s stock valued at $328,000 after purchasing an additional 60,248 shares in the last quarter. 10.03% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Imprimis Pharmaceuticals (IMMY) Stock Price Down 5.5%” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://sportsperspectives.com/2018/11/20/imprimis-pharmaceuticals-immy-stock-price-down-5-5.html.

Imprimis Pharmaceuticals Company Profile (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.

Recommended Story: What is the float in trading stocks?

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply